In today’s briefing:
- Oneness Biotech (4743 TT): Worth of Attention Ahead of Upcoming Key Milestones
Oneness Biotech (4743 TT): Worth of Attention Ahead of Upcoming Key Milestones
- Oneness Biotech (4743 TT)’s approved drug in Taiwan, Fespixon is the world’s first drug to treat diabetic foot ulcers with superiority in complete wound closure to the standard of care.
- Fespixon is under review in China, and is under multiple NDA submissions to Asian health authorities. The U.S. phase 3 study is expected to be completed in H1 2023.
- Key milestones are expected from two other late-stage pipeline drug candidates, FB825 and FB704A in 2022 and beyond.
Related tickers: Oneness Biotech (4743.TWO)
Before it’s here, it’s on Smartkarma
